strong close coming up, page-6

Solbec got a mention in "The West Australian" on Saturday. Independant analyst Peter Strachan selected Solbec for those investors looking for a "large punt". "The company has embarked on phase 1a/2b trials of its anti cancer drug - results from this work could lead to a licence agreement by the end of 2004, significantly re-rating the company".

This may have been enough to get the ball rolling. If the trials can reproduce even some of the results seen in SAS patients, it should get the big players interested.

Tom.